Occuity

We’re proud to share that Occuity has been named Innovator of the Year at the Thames Valley Business & Community Awards.

It’s always encouraging when the work you’re immersed in every day is recognised externally. The judges highlighted our non-invasive optical technology, our focus on precision and research excellence, and the real-world clinical impact we are striving to deliver. That means a lot to the whole team.

This award reflects the effort of an incredible group of engineers, regulatory and compliance specialists, quality teams, clinical collaborators and commercial colleagues who work tirelessly to turn complex science into practical, usable healthcare solutions.

A special mention as well to our CEO, Dan Daly who was shortlisted for Entrepreneur of the Year. Building a regulated MedTech company is not for the faint-hearted, and that recognition is well deserved.

Our COO Mark Jenkins and COO Sharon Branch proudly collected the award on behalf of the team.

As regional winners, we now go through to the national finals of the Great British Business & Community Awards in September. We’re looking forward to representing the Thames Valley on the national stage.

Read More: https://zurl.co/ejD1I

We passed £1million in our current raise on Republic at the start of the week!

More than 280 investors have now joined us on our mission to transform disease screening and diagnostics using the eye as a window to the health of the body.

Reaching £1 million is a powerful validation of our technology, our team and confidence in our long-term Oculomics strategy. It reflects the growing belief that handheld, non-contact optical devices like the PM1 and AX1 can reshape global healthcare — and that Occuity is the company to deliver that change.

We’re getting closer to our £1.1million target and the campaign will be closing soon.

Last week, our team achieved a major milestone: a world-first in vivo retinal imaging result using brand-new, non-invasive optical methods developed in our Reading labs.

This breakthrough allows us to distinguish different molecules in the retina in vivo with unprecedented precision — a step that could reshape early detection of both ocular and systemic disease. It’s a huge moment for our Future Leaders Fellowship programme and a powerful validation of the technology we’re building.

(It's frustrating that we cant share more than this, but our team are currently working on patent applications.)

👉 Join us tonight for a webinar, where our Head of Marketing, Richard Kadri-Langford will host a panel discussion with our Senior Leadership team.

If you’re interested in the future of eye-based diagnostics, early disease detection, or investing in high-impact MedTech, this is one you won’t want to miss.

🔗 Register here: https://zurl.co/Qb4ML

Occuity Achieves World-First Breakthrough in In Vivo Retinal Imaging Unprecedented In Vivo Retinal Imaging Achieved in Occuity’s Reading Labs